Serum tumour marker regression rate following chemotherapy for malignant teratoma
- 1 December 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (12) , 1463-1470
- https://doi.org/10.1016/0277-5379(84)90137-8
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Marker Half-Life Analysis as a Prognostic Tool in Testicular CancerJournal of Urology, 1982
- Serial monitoring of serum alpha-fetoprotein and chorionic gonadotropin in males with germ cell tumorsCancer, 1979
- Testicular Germ-Cell Neoplasms: Recent Advances in Diagnosis and TherapyAnnals of Internal Medicine, 1979
- CLINICAL USE OF A.F.P. AND H.C.G. IN TESTICULAR TUMOURS OF GERM-CELL ORIGINThe Lancet, 1978
- The Value of Serum Tumor Markers in the Staging and Prognosis of Germ Cell Tumors of the TestisJournal of Urology, 1977
- SERUM α1-FETOPROTEIN AND H.C.G. IN PATIENTS WITH TESTICULAR TUMOURSThe Lancet, 1976
- The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumorsCancer, 1976
- The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancyCancer, 1974
- Recent Observations Related To The Chemotherapy And Immunology Of Gestational ChoriocarcinomaAdvances in Cancer Research, 1973
- Alpha-Fetoprotein in Ontogenesis and its Association with Malignant TumorsAdvances in Cancer Research, 1971